MediWound (MDWD) Q2 2026 earnings review
Massive H2 Execution Needed to Save the Year
MediWound's Q2 2026 paints a picture of a company stretched financially while waiting for a massive second-half catalyst. Revenue declined 46% YoY to $3.1M, and operating losses widened to $9.5M as R&D spending for the EscharEx trial accelerated. Despite an exceptionally weak first half (totaling $4.6M in revenue), management reaffirmed full-year guidance of $24-$26M. This implies a staggering ~$20.4M revenue requirement in H2 2026, resting almost entirely on the newly signed Master Services Agreement with Vericel under a BARDA contract. With cash dwindling to $36M against a $20M H1 cash burn, MediWound has zero room for error. The long-term thesis (EscharEx's $1.05B market potential and NexoBrid's manufacturing scale-up) remains intact, but near-term liquidity and execution risks are heavily elevated.
🐂 Bull Case
The Master Services Agreement with Vericel under the up to $197M BARDA contract is officially signed. This shifts NexoBrid from a commercial product into a strategic government asset, virtually guaranteeing a massive revenue ramp in the second half of 2026.
The estimated U.S. peak sales potential for EscharEx was raised to $1.05 billion after expanding the assessment to include pressure ulcers (PUs). A new trial for PUs starts in Q4 2026, adding a third major chronic wound vector alongside VLUs and DFUs.
🐻 Bear Case
The company burned $20M in cash during H1 2026, leaving just $36M on the balance sheet. If the BARDA revenue ramp is delayed even by a single quarter, the company will face severe liquidity constraints and likely highly dilutive financing.
Gross margins collapsed from 23.5% a year ago to just 10.9%, driven by 'one-time' facility scale-up costs. Compounding this, R&D expenses surged 68% YoY. Operational leverage is currently moving aggressively in the wrong direction.
⚖️ Verdict: 🔴
Bearish. While the long-term clinical pipeline is promising, the reaffirmed 2026 guidance requires a near-perfect execution of government contracts in H2. The combination of a collapsing gross margin, widening operating losses, and a rapidly depleting cash pile creates an unacceptable risk profile until the BARDA revenue actually hits the income statement.
Key Themes
Severe Execution Risk in H2 Revenue Guidance
Management reaffirmed FY2026 revenue guidance of $24-$26 million. However, H1 2026 revenue was only $4.6 million. To achieve the $25 million midpoint, MediWound must generate $20.4 million in H2 2026—a 443% acceleration over the first half. This growth is entirely dependent on recognizing revenue from the new Vericel/BARDA Master Services Agreement. A single administrative delay at BARDA or Vericel would result in a massive earnings miss.
Cash Runway is Shrinking Rapidly
The company's cash position dropped to $36 million, down from $54 million at the end of 2025. H1 2026 cash burn was $20 million. At the current burn rate, MediWound has less than 12 months of runway remaining. While the anticipated H2 BARDA revenue will provide non-dilutive relief, any delay in collections contradicts management's narrative of financial stability.
Vericel Commercial Execution Accelerating
On the commercial side, U.S. partner Vericel is performing exceptionally well. Management noted Vericel achieved its strongest quarter since the launch of NexoBrid, with record quarterly revenue, hospital unit sales, and ordering centers. Approximately 80 burn centers have ordered NexoBrid since launch, proving strong underlying market adoption.
Manufacturing Facility Delays Limit Margin Improvement
Gross margin reversed sharply to 10.9% in Q2 2026, down from 23.5% YoY, citing 'facility scale-up' impacts. Furthermore, the new manufacturing facility faces EMA-requested operational modifications in H2 2026, pushing expected commercial supply to the second half of 2027. This means margin pressure will likely persist longer than previously anticipated.
Macro Tailwinds: Government Bioshield Initiatives
The up to $197 million BARDA contract validates NexoBrid as a critical asset for national security and emergency preparedness. By participating in the next-generation development program for blast- and friction-related injuries, MediWound is directly benefiting from increasing government focus on mass casualty preparedness—a highly stable, non-cyclical revenue source.
Other KPIs
Accelerating significantly from $3.5 million a year ago. This 68% YoY increase reflects heavy investments in the EscharEx Phase III VALUE trial. This is a structural drag on profitability that will persist until the trial's completion in early 2027.
Appears to be a YoY improvement from a $13.3 million loss in Q2 2025, but this is an accounting mirage. The improvement primarily reflects non-cash financial income (warrant revaluations). Operating loss, which reflects actual business performance, deteriorated to $9.5 million from $5.7 million.
Guidance
Reaffirmed. This implies severe acceleration. With H1 generating only $4.6M, the midpoint implies H2 2026 revenue of $20.4M. This relies heavily on the Master Services Agreement with Vericel under the BARDA contract commencing in the second half of the year.
Key Questions
BARDA Contract Visibility
Of the roughly $20 million in revenue required to hit the H2 2026 implied guidance, exactly how much is already contractually committed under the Vericel MSA versus dependent on new purchase orders?
Margin Compresssion Permanence
Gross margin collapsed to 10.9% due to 'facility scale-up' costs. Can you quantify the exact one-time dollar amount of this impact, and should we expect gross margins to remain below 20% until the facility achieves commercial supply in H2 2027?
Contingency for Regulatory Delays
With $36 million in cash and a $20 million H1 burn rate, what is the contingency funding plan if the EMA modifications to the manufacturing facility take longer than expected and push back FDA audits into late 2027?